Harnessing Neurogenic Potential of Glial Cell Types as an Emerging Strategy for Treating Epilepsy
- 1Laboratory of Cellular Neurobiology of Learning, Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences, Moscow 117485, Russia
Abstract
In every third case of epilepsy, anti-seizure drugs are ineffective, so the search for new therapies for this disease is ongoing. In recent years, new methods for generating cells with desired properties, as well as for the targeted expression of genes in specific cell types in situ within the brain, were designed. These methods allowed researchers to consider the idea of transforming resident glial cells into neurons in conditions like epilepsy; in such pathologies it may rescue both neuronal loss and gliosis. In this review, we describe epilepsy-associated pathological changes in glial cells, the neurogenic potential of different glial types (their similarities to neural stem cells and their inherent limited ability to produce neurons in response to brain damage), and existing methods of neuronal transdifferentiation starting with different cell types with varying proximity in lineage distance to neurons. Based on overlaps between these topics, we make conclusions about the applicability of glia-to-neuron conversion in treating epilepsy and the most important challenges that should be considered in designing experiments and clinical trials for this strategy.
Related
- Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.
- Cardiolipin-Specific Targeting of Melittin via Arg22 in Lipid Membranes: A Natural Toxin-Based Strategy for Treating Mitochondrial Dysfunction in Aging and Disease.
- The Boron–Neuron Connection: The Potential of Boron‐Containing Molecules for Treating Incurable Amyotrophic Lateral Sclerosis
- Harnessing Methylselenol (CH₃SeH): A Highly Effective Platform for Stimuli-Responsive Delivery With Therapeutic Potential.
- Potential Locations for Noninvasive Brain Stimulation in Treating Poststroke Deficits: Exploration From Multimodal Neuroimaging
BibTeX
@article{chesnokova2026harnessing,
title = {{Harnessing Neurogenic Potential of Glial Cell Types as an Emerging Strategy for Treating Epilepsy}},
author = {Ekaterina Chesnokova and Irina Kotova and Anna Reznikova and Pavel Balaban and Natalia Bal},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27209147},
url = {https://www.mdpi.com/1422-0067/27/20/9147},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Harnessing Neurogenic Potential of Glial Cell Types as an Emerging Strategy for Treating Epilepsy
AU - Ekaterina Chesnokova
AU - Irina Kotova
AU - Anna Reznikova
AU - Pavel Balaban
AU - Natalia Bal
PY - 2026
DA - 2026/10/15
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27209147
UR - https://www.mdpi.com/1422-0067/27/20/9147
AB - In every third case of epilepsy, anti-seizure drugs are ineffective, so the search for new therapies for this disease is ongoing. In recent years, new methods for generating cells with desired properties, as well as for the targeted expression of genes in specific cell types in situ within the brain, were designed. These methods allowed researchers to consider the idea of transforming resident glial cells into neurons in conditions like epilepsy; in such pathologies it may rescue both neuronal loss and gliosis. In this review, we describe epilepsy-associated pathological changes in glial cells, the neurogenic potential of different glial types (their similarities to neural stem cells and their inherent limited ability to produce neurons in response to brain damage), and existing methods of neuronal transdifferentiation starting with different cell types with varying proximity in lineage distance to neurons. Based on overlaps between these topics, we make conclusions about the applicability of glia-to-neuron conversion in treating epilepsy and the most important challenges that should be considered in designing experiments and clinical trials for this strategy.
SN - 1422-0067
ER -